Video

Dr. Kumar on Ongoing Research in Multiple Myeloma

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses ongoing research in multiple myeloma.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses ongoing research in multiple myeloma.

The use of minimal residual disease (MRD) could lead to personalized treatment strategies in multiple myeloma, says Kumar. Currently, clinical trials are, in addition to evaluating novel combination regimens, incorporating MRD negativity status to guide individualized treatment approaches and schedules.

For example, in the phase III AURIGA trial, patients who are MRD positive following autologous stem cell transplant will be randomized to maintenance therapy with the combination of daratumumab (Darzalex) plus lenalidomide (Revlimid) versus lenalidomide alone to determine the optimal duration of maintenance therapy and the need for an CD38 antibody. Moreover, in the relapsed/refractory setting, genomics could take on a greater role in guiding individualized treatment decisions, concludes Kumar.

Related Videos
Dr Sullivan on RP1 Plus Nivolumab in Anti–PD-1–Refractory Melanoma
Neeta Somaiah, MD
Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
6368672538112
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
4 experts are featured in this series.